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Summary Heart involvement, including primary myocardial involvement, is very common in
systemic sclerosis. There is strong evidence that primary myocardial involvement is related
to repeat focal ischaemic injury causing subsequent irreversible myocardial ﬁbrosis. Clinically
evident cardiac involvement is recognized to be a poor prognostic factor; thus preclinical iden-
tiﬁcation is highly encouraged. The severity of heart involvement has been conﬁrmed recently.
Echocardiography, including pulsed tissue Doppler echocardiography, is the cornerstone of
routine heart assessment. Myocardial perfusion may be assessed by single photon emission
computed tomography. If available, cardiac magnetic resonance imaging should be considered
as it allows simultaneous measurement of ventricular volumes and function and myocardial
perfusion, and assessment of possible inﬂammation and/or ﬁbrosis. Biological variables, such
as B-type natriuretic peptides, are highly relevant, valuable markers of global heart involve-
ment in systemic sclerosis and should be considered for screening of patients and/or research
purposes.
© 2009 Elsevier Masson SAS. All rights reserved.
MOTS CLÉS
Myocarde ;
Résumé Les complications cardiaques sont fréquentes chez les patients atteints de scléro-
dermie systémique, y compris l’atteinte myocardique primitive. Il existe de solides arguments
pour afﬁrmer que cette atteinte myocardique primitive est la conséquence d’épisode répétés
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d’ischémie focale génératrice de ﬁbrose myocardique. L’atteinte cardiaque, lorsqu’elle est
décelable cliniquement est de très mauvais pronostic ; son identiﬁcation a un stade plus
précoce, préclinique, est recommandée. La sévérité de l’atteinte cardiaque a été conﬁr-
mée dans des études récentes. L’échocardiographie conventionnelle, incluant la mesure des
vélocités annulaires par doppler pulsé tissulaire, est considérée comme la pierre angulaire de
l’évaluation chez ces patients. La perfusion myocardique peut être étudiée par tomoscinti-
graphie myocardique. Lorsqu’elle est réalisable, l’IRM s’avère être un outil de choix car elle
permet de mesurer les volumes ventriculaires, la fonction ventriculaire gauche et droite, la per-
fusion myocardique et la recherche d’une possible atteinte myocardique inﬂammatoire et/ou
la ﬁbrose myocardique. Certains paramètres biologiques, les peptides natriurétiques de type B,
sont des marqueurs puissants d’atteinte cardiaque et pourraient être utiles pour la détection
des patients devant bénéﬁcier d’
pour la recherche.
© 2009 Elsevier Masson SAS. Tou
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DAbbreviations
CCB calcium channel blocker
CI conﬁdence interval
LVEF left ventricular ejection fraction
NT-pro-BNP N-terminal prohormone brain natriuretic pep-
tide
SSc systemic sclerosis
TDE tissue doppler echocardiography
Introduction
SSc is a connective tissue disease characterized by
widespread vascular lesions and ﬁbrosis of the skin and
internal organs. Cardiac involvement is often clinically
occult, but is recognized as a poor prognostic factor and
is one of the leading causes of mortality in patients with
SSc [1].
Cardiac involvement may affect the endocardium,
myocardium and pericardium, separately or concomitantly.
As a consequence, pericardial effusion, auricular and/or
ventricular arrhythmias, conduction disease, valvular regur-
gitation, myocardial ischaemia, myocardial hypertrophy and
heart failure have been reported. In addition, pulmonary
arterial hypertension and renal and lung involvement can
affect cardiac status adversely [1]. In order to narrow
the focus on speciﬁc involvement, most of the data
we present in this review relate to primary myocardial
involvement.
Prevalence and prognosis of overall
cardiac involvement
The prevalence of overall cardiac disease varies between
studies depending on the methods used for its assessment.
Most available data are based upon clinical evaluation, elec-
trocardiogram and thoracic X-ray. Several lines of evidence
suggest that both cutaneous subtypes could be affected by
cardiac involvement [1,2]. However, an Italian epidemio-
logical study suggested that heart involvement might be
more prevalent in the diffuse subtype (32%) than in the
limited form (23%) [2]. Such an association has been con-
ﬁrmed recently in a study that focused on depressed LVEF
and reported on more than 7000 patients [3]. In addition,
i
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sautres explorations cardiaques ou comme critère d’évaluation
s droits réservés.
ata from Perera et al. showed that antitopoisomerase I
ntibody-positive patients, with the limited or diffuse cuta-
eous subtype, and with rapid or intermediate skin thickness
rogression rate, are at considerable early risk of the occur-
ence of SSc-associated cardiac problems [4]. Indeed, 41% of
atients classiﬁed as being in the ‘‘rapid skin thickness pro-
ression subgroup’’ had cardiac involvement. Among those
atients with cardiac involvement, 75% developed cardiac
nvolvement within 3 years of the onset of skin thickening
4].
In an international meta-analysis, among 1645 cases,
78 deaths occurred over 11,521 person-years of follow-
p. In multivariable analyses adjusted for age and sex,
ardiac involvement (deﬁned by major conduction distur-
ances, ventricular arrhythmia, heart failure or persistent
oderate-to-large pericardial effusion detected by echocar-
iography) increased the risk of mortality (hazard ratio 2.8;
5% CI 2.1—3.8) as well as renal involvement (hazard ratio
.9; 95% CI 1.4—2.5), pulmonary involvement (hazard ratio
.6; 95% CI 1.3—2.2) and antitopoisomerase I antibodies
hazard ratio 1.3; 95% CI 1.0—1.6). Moreover, renal, cardiac
nd pulmonary involvement tended to occur concomitantly
5]. Such a severity has been conﬁrmed recently in a series
f 366 Hungarian patients; 65% of the observed deaths were
ttributed to cardiopulmonary complications of the disease
6].
Apart from cardiac involvement, pulmonary hypertension
ay also have a negative effect on the prognosis of patients
ith SSc. Indeed, two recent studies included patients
ith mean pulmonary arterial pressure ranging from 40 to
0mmHg [7,8]. Three-year survival ranged from 28 to 48%
n these studies and was reduced signiﬁcantly compared
ith primary pulmonary hypertension or systemic lupus
rythematosus-associated pulmonary hypertension [7,8]. As
ulmonary hypertension is often associated with both right
nd left ventricular involvement in SSc, one may speculate
hether such speciﬁc cardiac involvement contributes to
he observed high mortality rate [9].
ifferent manifestations of cardiac
nvolvement in SSc and their prevalence
Sc may be complicated by several distinct cardiac mani-
estations. Of these, depressed myocardial contractility is
upposed to be speciﬁc, and the ‘‘hallmark’’ of primary
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yocardial involvement. However, its existence and preva-
ence is still a matter of debate, as most studies have
eported a low prevalence of reduced LVEF [10—12]. One
rench multicentre study, which included 570 patients,
eported a 1.4% prevalence of left ventricular systolic
ysfunction [10]. Other authors have reported a low
revalence of depressed LVEF at rest, although up to 46%
f patients had left ventricular dysfunction when LVEF was
lso measured during exercise [11,13]. More recently, the
USTAR registry provided robust estimates of the prevalence
f left ventricular dysfunction. The EUSTAR registry is a
ulticentre, international database that has been described
n detail [14]. LVEF was classiﬁed as depressed when <50%
r 55%, according to each echocardiographic laboratory.
he EUSTAR registry collected data from 7073 consecutive
atients (mean age 56± 14 years) and demonstrated an
verall 5.4% prevalence of reduced LVEF [3].
We have reported previously the observation of reduced
eft ventricular contractility despite a normal LVEF, using
adial strain rate determined by TDE, suggesting that the
revalence of depressed myocardial contractility may be
nderestimated [15,16]. In a more recent study, we inves-
igated 100 consecutive patients with SSc and matched
ontrols, using conventional echocardiography implemented
y pulsed TDE mitral and tricuspid annular velocity measure-
ents [9]. Using this simple and widely available method,
e demonstrated that 14% and 15% of patients with SSc had
educed left and right ventricular contractility, respectively
9].
The presence of diastolic dysfunction in patients with SSc
as been demonstrated extensively [10—12]. However, the
istinction between pathological ﬁndings and age-related
hanges or other confounding factors may be hard to ascer-
ain. In the largest study, the authors reported the presence
f diastolic abnormalities in 101 of 570 patients (17.7%)
10]. However, 48 (8.4%) patients had a restrictive mitral
ow pattern, which is unequivocally abnormal, while 53
9.3%) patients had delayed diastolic relaxation, which,
n the absence of a control group, does not allow formal
onclusions to be made [10]. In our controlled study, using
ulsed TDE, we found that 30 of 100 patients had deﬁnite
bnormal left ventricular ﬁlling [9]. Overall, the prevalence
f diastolic dysfunction was increased compared with age-
nd sex-matched controls [9], and ranged from 17 to 30%
9,10].
Primary pulmonary arterial hypertension is assumed to
e rare but is one of the most severe complications of SSc.
n one of the largest series, the French ITINERAIR cohort,
ts prevalence was 7.85% [7]. Other series reported similar
esults, and its prevalence ranges from 8 to 12% overall,
ccording to the various series [17].
Pericardial effusion has been noted in 33 of 77 (43%) SSc
atients versus two of 45 (4%) controls, but only 11 of 77
14%) had a signiﬁcant effusion, according to a controlled
tudy [11]. In our study, 15 of 100 (15%) patients compared
ith one of 26 (4%) controls had pericardial effusion (dif-
erence not signiﬁcant) [9]. In addition, we demonstrated
hat SSc patients had a higher prevalence of aortic regur-
itation (18%) and a trend towards more prevalent mitral
egurgitation; however, valvular regurgitations were associ-
ted with age, and most patients had grade I aortic or mitral
egurgitation, or both (a benign ﬁnding) [9].
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athophysiology of primary myocardial
nvolvement
Sc vascular lesions result in general impairment of the
icrocirculation. Despite the predominance of vascular
bnormalities and documented ischaemia, some studies do
ot support a higher prevalence of atherosclerotic coronary
rtery disease in SSc patients than in the general population
13,18]; however, the exact prevalence of atheroscle-
otic coronary artery disease remains to be determined.
yocardial ﬁbrosis is thought to occur after repeated focal
schaemia, resulting from abnormal vasoreactivity, with
r without associated structural vascular disease. Studies
emonstrating the effect of vasodilator agents on perfusion
bnormalities further emphasize the potential role of coro-
ary vasospasm. The observations by SPECT of myocardial
erfusion defects unrelated to coronary artery distribu-
ion and the reversibility of some perfusion defects after
asodilator treatment, which coexist with ﬁxed defects,
o suggest the coexistence of ischaemic lesions such as
asospasm and irreversible lesions such as organic vessel
isease or myocardial ﬁbrosis [1]. Indeed, some histologi-
al examinations have revealed diffuse patchy ﬁbrosis, with
ontraction band necrosis unrelated to epicardial coronary
rtery stenosis [19], whereas other studies have revealed
oncentric intimal hypertrophy associated with ﬁbrinoid
ecrosis of intramural coronary arteries [20]. Typical patho-
ogical ﬁndings include disseminated plaques of myocardial
brosis, normal epicardial coronary arteries but arteriolar
oncentric intimal hypertrophy, which leads to impaired
oronary reserve (Fig. 1).
isk factors for primary myocardial
nvolvement
o investigate the potentially relevant risk factors for
yocardial involvement, we ﬁrst studied the EUSTAR
atabase [3]. By multiple regression analysis, age, sex,
iffuse cutaneous disease, disease duration, digital ulcera-
ions, renal and muscle involvement, disease activity score,
ulmonary ﬁbrosis and pulmonary arterial hypertension
ere associated with left ventricular dysfunction [3]. In
second phase, we performed a case-control study of a
atient subset of the EUSTAR database, to further iden-
ify independent factors associated with left ventricular
ysfunction by simple and multiple regression, includ-
ng variables not registered in the EUSTAR database, and
atched for disease duration. Overall, 129 SSc patients
ith LVEF <55% were compared with 256 SSc patients with
ormal LVEF, and we demonstrated that male sex (odds
atio 3.48; 95% CI 1.74—6.98), age (odds ratio 1.03; 95%
I 1.01—1.06), digital ulcerations (odds ratio 1.91; 95% CI
.05—3.50), myositis (odds ratio 2.88; 95% CI 1.15—7.19) and
o use of CCBs (odds ratio 0.41; 95% CI 0.22—0.74) were inde-
endent factors associated with left ventricular dysfunction
3]. Interestingly, typical cardiovascular risk factors were
ot associated with a reduced LVEF. Overall, these ﬁndings
ay suggest that markers of severity of SSc, as well as mark-
rs of microvascular lesions (i.e., digital ulcerations), are
ssociated with reduced LVEF.
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adequate, as it is a simple, safe and reproducible test that isFigure 1. Heart histological analyses. SSc patient with end-stage
heart failure requiring heart transplantation; acknowledgments to
Pr Jean-Baptiste Michel Inserm U698, CHU Bichat, Paris, France.
Another important ﬁnding of the nested study was the
markedly lower proportion of patients with reduced LVEF
who had been treated previously with CCBs, especially for
>12months [3]. In addition, this study suggests that immuno-
suppressive therapies are not associated with reduced
cardiac involvement [3]. However, our registry does not
allow the efﬁcacy of immunosuppressors to be ruled out in
the speciﬁc context of myocarditis associated with SSc.
From a different perspective, our study suggests strongly
that CCBs have protective effects against the development
of left ventricular dysfunction. Our result is concordant with
previous short-term studies, which showed beneﬁcial effects
conferred by CCBs on myocardial perfusion and function,
using various methods of assessment [1,21,22]. In patients
presenting with the limited cutaneous SSc subtype, Steen
and Medsger found that patients presenting with pulmonary
arterial hypertension were treated with CCBs signiﬁcantly
less often than patients without pulmonary arterial hyper-
tension [23].In another study, the development of digital ulcers was
also delayed by vasodilator therapy [24]. Altogether, these
observations suggest that CCBs protect against microvascu-
lar complications, including in the heart. Therefore, pending
u
h
b
i49
he results of long-term prospective study, we recommend
he broad use of CCBs in patients with SSc, unless contraindi-
ated.
ssessment of heart involvement
few decades ago, radionuclide ventriculography was rec-
mmended for heart function assessment. While it has been
upplanted progressively by echocardiography, it should be
till considered in some patients with poor echogenicity
<5%) and for research purposes. Doppler echocardiogra-
hy together with clinical evaluation has been proposed as
he candidate method for routine cardiac assessment, as it
hould detect all types of SSc cardiac complications [25].
Recent studies suggest, however, that these indexes may
ack sensitivity and do not allow a prompt diagnosis at a pre-
linical stage, when therapeutics are supposed to be more
ffective. Indeed, new methods such as magnetic resonance
maging and strain rate imaging have been shown to be
ore sensitive methods than conventional echocardiography
9,15,16,26]. While these methods should be encouraged
or research purposes, we acknowledge that they may not
e recommended for standard evaluation. Pulsed TDE has
merged in recent years as a robust indicator of both left
nd right ventricular contractility, as well as left ventricular
lling patterns. In the speciﬁc context of SSc, we and others
ave demonstrated that the implementation of conventional
chocardiography with mitral and tricuspid annular veloci-
ies measurements resulted in greater detection of cardiac
omplications [9]. Considering the availability of pulsed
DE, it has been suggested that it should be considered for
outine evaluation of patients with SSc [9].
The investigation of myocardial perfusion and microcir-
ulationmay also be considered for some SSc patients. Single
hoton emission computed tomography was proposed a few
ears ago for the assessment of myocardial perfusion abnor-
alities and possibly for distinguishing reversible ischaemia
rom irreversible lesions. However, this procedure is limited
n quantitative studies [1] and has been supplanted progres-
ively by cardiac magnetic resonance imaging, as it allows
he identiﬁcation of small subendocardial perfusion defects,
ut also coronary ﬂow reserve determination, the identiﬁ-
ation of myocarditis (especially in patients with myositis)
nd the morphological evaluation of ﬁbrotic myocardium
ompared with viable tissue [27] (Figs. 2 and 3). In addi-
ion, cardiac magnetic resonance imaging also appears to be
rapid and non-invasive means of determining subclinical
ight myocardial involvement [28] and is under develop-
ent for the assessment of the right ventricle in secondary
eart involvement related to pulmonary arterial hyperten-
ion [29].
With respect to the various possible cardiac compli-
ations of SSc, and considering the impact of repeated (at
east twice a year) echocardiography coupled with pulsed
DE, screening methods may be advocated.
One would think that the 6-minute walk test might besed largely in the evaluation of several moderate-to-severe
eart or lung diseases. However, conﬂicting results have
een reported regarding its use in SSc. In a recent study, we
nvestigated 87 patients with SSc and demonstrated that the
50 C. Meune et al.
Figure 2. Cardiac magnetic resonance imaging. Left ventricular
short-axis acquisition immediately after the injection of gadolin-
ium (a: ﬁrst-pass myocardial perfusion) and 10min after injection
(b: delayed enhancement). Early subendocardial hypoenhancement
of the left ventricular lateral wall shown on ﬁrst-pass perfusion is
related to impaired microcirculation (coronary computed tomogra-
phy angiography was normal). Delayed enhancement exhibits linear
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ity. Moreover, we demonstrated that NT-pro-BNP detected
accurately patients with depressed myocardial contractil-
ity and overall cardiac involvement (area under the curve
0.905 [0.814—0.996] and 0.935 [0.871—0.996], respectively)
(Fig. 4) [34]. Considering SSc patients with normal echocar-ubendocardial hyperenhancement in the lateral wall and focal
ntramyocardial hyperenhancement in the septal wall, highly sug-
estive of myocardial ﬁbrosis.
-minute walk test relates to broad factors; our results ques-
ion highly the speciﬁcity of the 6-minute walk test in this
ystemic disease and its relevance for monitoring therapy in
he context of SSc [30].
A more attractive solution is the use of natriuretic pep-
ides. Indeed, we have demonstrated that elevated serum
T-pro-BNP is a sensitive and speciﬁc diagnostic marker
f early elevated systolic pulmonary artery pressure in
Sc [31]. In another study, NT-pro-BNP levels correlated
ith haemodynamics and prognosis in patients with estab-
ished pulmonary arterial hypertension [32]. Recently, we
uggested that both lung diffusion carbon monoxide capac-
ty and NT-pro-BNP levels can be used to identify SSc
atients at high risk of the development of pulmonary
rterial hypertension [33]. Apart from their role in the
etection/management of pulmonary arterial hypertension,
atriuretic peptides are candidate markers for the detec-
ion of left/right ventricular dysfunction. In a recent article,
e reported a study of 69 consecutive patients with SSc
mean age 56± 13 years, 56 women) using echocardiography
nhanced by pulsed TDE measurements, and plasma NT-pro-
F
d
bigure 3. Cardiac magnetic resonance imaging. Left ventricular
hort-axis acquisition immediately after the injection of gadolin-
um. Early hyperenhancement of the left ventricular inferior wall
elated to myocardial inﬂammation.
NP [34]. Overall, 18 patients had manifestations of cardiac
nvolvement, of whom seven had depressed left ventricular
yocardial contractility, eight had depressed right ventric-
lar myocardial contractility and eight had elevated systolic
ulmonary arterial pressure. In this study, we conﬁrmed
hat NT-pro-BNP correlated with pulmonary arterial pressure
nd correlated inversely with left ventricular contractil-igure 4. Receiver operating characteristic (ROC) curve for the
etection of overall cardiac involvement by N-terminal prohormone
rain natriuretic peptide.
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diography and TDE as controls, and using a 125 pg/mL cut-off
concentration as recommended by the manufacturer for
ambulatory patients, sensitivity and speciﬁcity were 92% and
71% in the detection of depressed myocardial contractility
and 94% and 78% for overall cardiac involvement, respec-
tively [34].
Recommendations for assessing heart
involvement in routine practice
Doppler-echocardiography together with clinical evaluation
should be considered for routine cardiac assessment [25].
Given the broad availability and sensitivity of pulsed TDE, we
believe that it should be included in all cardiac evaluations
in routine practice [9].
B-type natriuretic peptides have emerged in recent years
as candidate markers for the diagnosis of both pulmonary
hypertension and primary myocardial involvement in the
speciﬁc context of SSc [34]. Given the simplicity, robust-
ness and wide availability of brain natriuretic peptide and
NT-pro-BNP assays, we recommend its use for the detection
of any cardiac involvement in SSc patients, and believe that
it might become the test of ﬁrst choice for risk stratiﬁcation
and for following the cardiac status of patients with SSc.
Magnetic resonance imaging should be considered in
some selected SSc patients to investigate myocardial per-
fusion and microcirculation or in the context of suspected
myocarditis.
Conclusion
Cardiac involvement occurs frequently in SSc and clinicians
should not focus solely on pulmonary arterial hypertension.
Thanks to recent innovations, clinicians have a large panel
of methods, some of which should possibly be reserved for
research, and others that seem to be widely available and
suitable for routine clinical practice. Indeed, conventional
echocardiography, pulsed TDE and natriuretic peptides may
be used for routine assessment. Magnetic resonance imaging
and strain rate imaging are unavailable for routine use as
yet, and may only be considered in speciﬁc patients or for
research purposes.
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